Genetic susceptibility to systemic lupus erythematosus (SLE) is suggested by population and family studies, particularly as the concordance rate in monozygotic twins is at least 1 0-fold that of dizygotic twins. ' Clinical manifestations of SLE were not associated with particular HLA genotypes, but there was a significant association between HLA-DQB1*02 and Ro antibodies. Thus in the subgroup of 37 patients who had been typed for anti-Ro and for whom an unequivocal DQ type could be assigned, 12/22 anti-Ro positive patients were also DQB1*02 positive (OR= 7-8; 95% CI = 1 24 to 48-89, p = 00 11). The association between anti-Ro and DR3 was somewhat weaker (p = 0-06).
Discussion
The increase in HLA-DR2 in our study is reflected in only one study of black SLE patients from North America.6 Although two studies have shown an association with DR3,5 6 at least three others have shown no HLA-DR or -DQ associations.4'8 9 Clinical heterogeneity between the groups studied has been invoked to explain this, but when studying populations of African origin one must also take account of the potential for substantial genetic variation. '4 Therefore, ethnic heterogeneity of the black North Americans in these studies could mask real associations-a problem we have overcome by selecting SLE patients and controls with careful regard to their ethnic affiliations. The association of SLE with HIA-DQB1*0602 in this population appears to be secondary to linkage disequilibrium with HLA-DRB1*02, as the empirical logistic test favours the latter allele as being of primary importance.
The recently suggested association of SLE with HLA-DQA1*0501 in white populations2 does not appear to cross racial boundaries, as in our study only 32% of the patients were positive for DQA1*0501, compared with 37% of the controls. In contrast, the association of DR2 with SLE does cross racial boundaries, as positive associations have also been reported previously in white and Asian populations. '5 The frequencies of autoantibodies to Ro (61%), ribonucleoprotein (72%), and Sm (50%) in these South Africans with SLE are greater than has been previously observed in black or white Americans.4 7 9 HLA-DQB 1*02 and, to a lesser extent DRB1*03, were associated with antibodies to Ro, but not with the disease itself. An association of both these alleles with Ro antibodies in SLE patients has been reported previously,9 but it is likely that the DRB1*03 association is secondary to linkage disequilibrium with DQB1*02. The variable strength of this linkage disequilibrium in different racial groups could also account for the variable association of DRB1*03 with SLE in different races. Thus among the DRB1*03 bearing haplotypes in the black South Africans, only 50% were also DQB1*02 (data not shown), compared with 100 per cent in white subjects. The greater diversity of DR3 haplotypes in black South Africans may indicate that only a minority bear the putative 'SLE gene' in contrast with white subjects. The nature of this HLA-linked gene remains to be established, but would include the C4A locus which has been incriminated in the aetiology of SLE in other studies in white popula- 2 4 tions.
In conclusion, there is evidence from our results for an SLE susceptibility locus on a DR2 haplotype in black South Africans. Furthermore, DQB1*02 which is not linked to DRB 1*02 is associated with the presence of Ro antibodies, which suggests the existence of at least two unlinked MHC loci contributing to SLE in this population.
